Early Access — free while we kick the tires
EdgarHawk

ONCO Onconetix, Inc. Insider Trading

Latest: Insider Bought $25K of Shares · Apr 2026
2 filings analyzed · Latest 2026-04-21
Insider buys
2
Insider sells
0
Unique insiders
1
Direction
Net buying
April 2026
2026-04-21
high
HRT FINANCIAL LP Buy
34,636 shares
$25,284
@ $0.73
Significance 7/10

10% owner HRT Financial LP sold 148.3K shares (57.7% of holdings) at $0.73–$0.75 while stock down -98.3% from $394.40 high.

HRT Financial LP filed 2 separate sales totaling 148,329 shares for $110,169.41 between April 16–20, 2026, reducing holdings from 197,052 to 83,359 shares (a -57.7% net reduction). The sales occurred at $0.73 and $0.75 per share, in a company trading at $6.77 with a 52-week range of $6.77–$394.40 and a -98.3% decline from the 52-week high; Onconetix reported a -67.7% annual revenue decline, $303.7K latest-quarter revenue, and a $-8.8M net loss over the full prior fiscal year. The filing also included 1 purchase of 34,636 shares at $0.73 on April 17, interleaved between the two sales, making this a mixed transaction rather than a unidirectional liquidation. HRT's cross-ticker track record shows 7 prior sells with an average 90-day return of +307643.6% (poorly timed—stock typically rose after the sales), but same-ticker history at ONCO is nascent, with no measurable outcomes yet. The scale of this reduction, the fundamental deterioration, and the stock's catastrophic price collapse warrant investor attention to understand whether the insider view has shifted regarding Onconetix's trajectory.

2026-04-16
high
HRT FINANCIAL LP Buy
166,904 shares
$127,591
@ $0.76
Significance 6/10

HRT Financial LP (10% Owner) bought 166,904 shares at $0.76 avg ($127.6K) as stock plunges -98.1% from 52-week high; company reports -$8.8M net income, revenue down -67.7% YoY.

HRT Financial LP acquired 166,904 shares across 2 transactions at a blended average price of $0.76, increasing its holdings by +553.6% to 197,052 shares total. The timing coincides with severe deterioration in Onconetix's fundamentals: the company reported net income of -$8.8M against quarterly revenue of only $303.7K, and annual revenue contracted -67.7% year-over-year. More broadly, the stock has collapsed -98.1% from its 52-week high of $394.40 to the current $7.60, with a -90.6% decline over the past 90 days. A 10% owner accumulating shares at depressed levels during operational distress warrants close attention to whether this reflects conviction in a turnaround or reflects a liquidity concern masked by transaction formality.

Insiders here also file at

Get alerts for ONCO

Add ONCO to your watchlist and we'll email you when an insider files a Form 4 — with our AI's significance score and a plain-English read of what it means.

Sign up — free during early access